Helsinn Healthcare News and Activities

View the org chart displaying its 16 main executives

Most searched biographies at Helsinn Healthcare

• Melanie Rolli, Group Chief Executive Officer
• Riccardo Braglia, Board Member
• Gabriele Braglia, Chairman of the Board

Create your alert
to follow the executive moves at Helsinn Healthcare.

Helsinn Healthcare has 1,829 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• Cyclo Therapeutics has acquired Rafael Holdings (posted on April 28 2025).
• Chimerix and Chimerix have merged  (posted on April 22 2025)..
• Imbria Pharmaceuticals has just announced a $58 Million fundraising (posted on April 10 2025).

Popular contacts in Pharmaceuticals

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets at Bristol-Myers Squibb
• Seth Harrison - Chairman and Director at Braeburn Pharmaceuticals
• Fred Davenport - Lead Director at Medpace

Learn more about the Pharmaceuticals industry

Press releases by Helsinn Healthcare

• News - Helsinn
• News and Events - Helsinn
• https://www.helsinn.com/news-and-events/taiho-pharmaceutical-submits-new-drug-application-for-nk1-receptor-antagonist-fosnetupitant-for-prevention-of-gastrointestinal-symptoms-nausea-and-vomiting-associated-with-cancer-chemotherapy/
• https://www.helsinn.com/news-and-events/helsinn-publishes-prove-mf-ctcl-study-providing-new-data-for-mechlorethamine-gel-use-in-a-real-world-setting/
• Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
• https://www.helsinn.com/news-and-events/announcement-of-approval-to-manufacture-and-market-5-ht3-serotonin-receptor-antagonist-antiemetic-agent-palonosetron-i-v-injection-palonosetron-i-v-infusion-bag-in-japan/
• ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
• An interview with Dr. Larisa Geskin on an MF-CTCL fellowship at Columbia University supported by Helsinn
• Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
• https://www.helsinn.com/news-and-events/helsinn-demonstrates-commitment-to-raising-awareness-on-cachexia-by-supporting-cachexia-societies-conferences/
• View more press releases Close

Social media about Helsinn Healthcare

• Helsinn Healthcare on Wikipedia, Google News & Yahoo Finance
• Helsinn Healthcare on LinkedIn, Twitter & YouTube